Nohla Therapeutics Launches with Major US Cancer Research Institute Deal, Substantial Investment Round, and Key Appointments Nohla Therapeutics Inc. announced the signing of an exclusive licensing and collaboration agreement with the Fred Hutchinson Cancer Research Center. [Nohla Therapeutics Inc. (Business Wire)] Press Release ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumor Consortium for ICT-107 Phase III Registrational Trial in Glioblastoma ImmunoCellular Therapeutics, Ltd. announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the Phase III registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma. [ImmunoCellular Therapeutics, Ltd.] Press Release Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-Esophageal Junction Cancers Merck KGaA, Darmstadt, Germany, and Pfizer announced the initiation of two Phase III studies of avelumab, an investigational, fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction cancers, which are aggressive cancers with poor survival rates. [Pfizer Inc.] Press Release BioLineRx Announces Regulatory Submission for Phase II Trial of BL-8040 as Novel Stem Cell Mobilization Treatment BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced the filing of regulatory submissions required to commence a Phase II trial for BL-8040 as a novel approach for mobilization and collection of bone marrow stem cells from the peripheral blood circulation. [BioLineRx Ltd.] Press Release Unum Therapeutics Announces Recombinant DNA Advisory Committee’s (RAC) Unanimous Approval of Phase I Study Protocol to Evaluate ACTR Cell Therapy in Non-Hodgkin Lymphoma Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced that it has received unanimous approval by the National Institute of Health’s RAC for its first U.S.-based clinical trial. [Unum Therapeutics] Press Release Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial Eli Lilly and Company and Merck announced another immuno-oncology collaboration that will evaluate abemaciclib, Lilly’s cyclin-dependent kinase 4 and 6 inhibitor, and Merck’s KEYTRUDA® in a Phase I study across multiple tumor types. [Eli Lilly and Company] Press Release Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy Bellicum Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Agensys, Inc. and Bellicum have entered into a global license agreement, granting Bellicum rights to develop and commercialize adoptive cell therapies, including CAR-T cells, for tumors expressing prostate stem cell antigen (PSCA) using PSCA technology, both in-licensed and developed at Agensys. [Bellicum Pharmaceuticals, Inc.] Press Release Kadimastem Reached Agreements with the FDA Regarding the Framework of the Clinical Trials in Humans for the Treatment of ALS Kadimastem announced that following a meeting it held in November with the FDA there is agreement with the FDA regarding the framework of the company’s future plans. The meeting with the FDA concerned the company’s cell-based product for the treatment of ALS. [Kadimastem] Press Release FDA Advisory Committee Recommends Approval of Teva’s Asthma Biologic Reslizumab Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee recommended approval of reslizumab, a humanized anti-interleukin-5 IgG4K monoclonal antibody, in adult patients aged 18 years and older. [Teva Pharmaceutical Industries Ltd.] Press Release Amarantus Retains WallachBeth Capital to Evaluate Strategic Options for MANF Gene Therapy Program Amarantus BioScience Holdings, Inc. announced that it has retained WallachBeth Capital to evaluate strategic options for its MANF gene therapy program. [Amarantus BioScience Holdings, Inc.] Press Release |